GlassScriptPhysician profile
Jennifer E Aldrich
NPI 1336282060
$3,414.47
in general payments reported to CMS, 2019-2025
24 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $284 · 2021: $28.44 · 2022: $238 · 2023: $428 · 2024: $498 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203 · Entertainment: $15.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.74 |
| Entertainment | $15.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $860.39 | 2019-2023 | Wegovy |
| Abbvie INC. | $742.00 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $353.51 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $343.12 | 2019-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $183.89 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $131.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.64 | 2019 | |
| Glaxosmithkline, LLC. | $89.87 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $77.32 | 2019 | |
| Merck Sharp & Dohme LLC | $76.55 | 2019-2023 | Belsomra |
| Pfizer INC. | $75.98 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $70.80 | 2019-2022 | |
| Allergan, INC. | $35.12 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $34.66 | 2022 | |
| Amarin Pharma, INC. | $31.81 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.55 | 2019-2024 | Trulance, Xifaxan |
| Seqirus USA INC | $30.04 | 2020 | |
| Eisai INC. | $27.04 | 2019 | |
| Astellas Pharma US INC | $23.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.21 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.78 | 2019 | |
| Therapeuticsmd, INC. | $16.30 | 2019 | |
| Optos, INC. | $15.59 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Sanofi Pasteur INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Aldrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.